Harnessing immunity for therapy in human papillomavirus driven cancers

Area of Science:

• Oncology
• Immunology
• Virology

Background:

• Persistent high-risk Human Papillomavirus (HPV) infection drives immune evasion in early lesions.
• HPV oncogene expression promotes tumor growth and immune escape by upregulating immune checkpoint ligands like PD-L1.
• Current immunotherapies, including checkpoint inhibitors and vaccines, show limited efficacy in advanced HPV-associated cancers.

Purpose of the Study:

• To explore strategies for overcoming immune suppression in HPV-associated cancers.
• To evaluate the potential of combining conventional therapies with immunotherapies for enhanced anti-tumor responses.
• To investigate the role of chemotherapy and radiotherapy in restoring anti-tumor immunity.

Main Methods:

• Review of current understanding of HPV-induced immune suppression mechanisms.
• Analysis of existing data on HPV therapeutic vaccination and immune checkpoint inhibitors.
• Exploration of combination strategies involving chemotherapy, myeloid cell reduction, and therapeutic vaccination.

Main Results:

• Chemotherapy combined with HPV vaccination and reduction of immunosuppressive myeloid cells significantly enhances cancer treatment impact.
• While checkpoint inhibitors show some efficacy, response rates in HPV-associated cancers remain limited.
• Therapeutic HPV vaccination has shown efficacy in high-grade lesions but not advanced cancers.

Conclusions:

• Countering HPV-induced immunosuppression is crucial for effective anti-tumor immunity.
• Combination therapies, particularly chemotherapy with therapeutic HPV vaccination, offer a promising approach.
• Further research is needed to optimize the sequencing and deployment of conventional and immunotherapies for HPV-associated cancers.